How GLP-1 Receptor Activators May Influence Immune and Metabolic Processes in Long-Term Inflammatory Skin Diseases
Updated
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce inflammation in chronic inflammatory skin diseases.
- Chronic inflammatory skin diseases are linked with systemic immune dysregulation and metabolic disorders.
- GLP-1RAs, commonly used for type 2 diabetes and obesity, may possess anti-inflammatory and immunomodulatory effects.
- GLP-1 signalling influences keratinocyte function, immune cell activity, and wound healing.
- It modulates various intracellular signalling pathways, including cAMP/PKA, AMPK, PI3K/Akt, and NF-κB.
- Current evidence on the effects of GLP-1RAs in dermatology is limited to experimental studies and small observational studies.
Simplified
Funding
Competing interests
The authors declare no conflicts of interest.
PubMed